Rhumbline Advisers Graphite Bio, Inc. Transaction History

Rhumbline Advisers

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 08, 2024	SELL	$2.24 - $2.66 $5,620 - $6,673	-2,509 Reduced 7.44%	31,202 $81,000
Q3 2023 Nov 09, 2023	BUY	$2.18 - $2.77 $10,065 - $12,789	4,617 Added 15.87%	33,711 $83,000
Q2 2023 Aug 08, 2023	BUY	$2.47 - $3.38 $71,862 - $98,337	29,094 New	29,094 $75,000
Q2 2022 Aug 11, 2022	SELL	$2.14 - $5.23 $52,772 - $128,971	-24,660 Closed	0 $0
Q1 2022 May 12, 2022	BUY	$5.1 - $13.06 $66,167 - $169,440	12,974 Added 111.02%	24,660 $126,000
Q4 2021 Feb 10, 2022	SELL	$8.41 - $16.71 $504 - $1,002	-60 Reduced 0.51%	11,686 $145,000
Q3 2021 Nov 12, 2021	BUY	$15.81 - $28.39 $185,704 - $333,468	11,746 New	11,746 $193,000

637K

Ticker GRPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,211,200
Description
Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH101, a gene-edited autologous hematopoietic stem cell product candidate to directly correct the mutation that causes sickle cell disease and restore normal adult hemoglobin expres...

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

Stay updated on Rhumbline Advisers with notifications on news.